Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
暂无分享,去创建一个
A. D. Dei Tos | P. Casali | T. Negri | S. Pilotti | A. Gronchi | C. Morosi | S. Stacchiotti | N. Zaffaroni | A. Toss | G. Grignani | R. D. Spagnuolo | E. Pennacchioli | G. Badalamenti | G. Baldi | G. Dagrada | S. Provenzano | D. Cominetti | M. Tortoreto | E. Fumagalli | F. Festinese | A. Tos
[1] P. Casali,et al. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy , 2014, British Journal of Cancer.
[2] C. Fournier,et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) , 2013, Investigational New Drugs.
[3] C. Morosi,et al. Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics , 2013, Clinical Cancer Research.
[4] L. Mariani,et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. , 2013, European journal of cancer.
[5] N. Zaffaroni,et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. , 2013, Biochemical pharmacology.
[6] K. Pienta,et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.
[7] C. Fletcher,et al. WHO classification of tumours of soft tissue and bone , 2013 .
[8] J. Blay,et al. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience , 2013, BMC Cancer.
[9] A. D. Dei Tos,et al. Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[11] Robin L. Jones,et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour , 2012, Acta oncologica.
[12] M. Bhasin,et al. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma , 2011, Journal of Translational Medicine.
[13] A. Lazar,et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor , 2011, Cancer.
[14] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[15] G. Alí,et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. , 2011, Neoplasia.
[16] T. Choueiri,et al. Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.
[17] A. Cesne,et al. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour , 2010, Investigational New Drugs.
[18] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Tonon,et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma , 2006, Proceedings of the National Academy of Sciences.
[20] F. Mertens,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .